Compare Vistra Corp (VST) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vistra Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Vistra Corp trades at $146.81 (market cap $48.64B), while State Street SPDR S&P Biotech ETF trades at $159.5. The key difference: Vistra Corp pays a 0.63% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Vistra Corp nearer its low. Which is the better fit depends on your goals.
| VST | XBI | |
|---|---|---|
Market Cap | $48.64B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $217.92 | $164.28 |
52-Week Low | $134.71 | $86.92 |
Enterprise Value | $70.58B | — |
Dividend Yield | 0.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VST trades at $146.36, up 2.44% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings with $1.767 billion adjusted EBITDA, beating expectations, while maintaining 2026 guidance. Valuation metrics show a P/E of 24.44 and robust profitability with 75.73% ROE, though recent earnings have been inconsistent with two misses in the last four quarters.
VST presents a compelling growth story driven by data center power demand and nuclear assets, with 90.9% analyst buy ratings and a $239.75 price target suggesting 64% upside. Key risks include ERCOT pricing volatility and hedging losses, while institutional interest remains strong with recent strategic acquisitions positioning the company for AI infrastructure growth.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vistra Corp
Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
